Jul 2026· Journal of Immunology· Vol 215· 0 citations
TL;DR
The results of these studies definitively demonstrate that NKG2D in CD8+ T cells plays a critical role in autoimmune diabetes, and show this role is to enhance CTL generation rather than the CTL effector response in islets as previously proposed.
Abstract
Type 1 diabetes (T1D) is an autoimmune disorder caused by T cell-mediated destruction of pancreatic β cells. There is a critical need to develop novel therapies for this disease, which requires further understanding of T1D pathogenesis. One pathway that is implicated is signaling through the immune receptor NKG2D. However, NKG2D’s role has remained unclear due to conflicting reports in the literature.
We generated multiple novel mouse strains on the non-obese diabetic (NOD) background to better define the role of NKG2D in autoimmune diabetes. We compared diabetes incidence, insulitis, including digital spatial profiling, and islet-specific CD8+ CTL generation between mice genetically deficient in NKG2D (NKG2D KO) and wild-type (WT) mice housed in both specific-pathogen-free (SPF) and germ-free (GF) conditions.
NKG2D KO mice had delayed diabetes, insulitis, and CD8+ T cell pancreatic infiltration, with the most significant effect in GF and male mice. Further, we found that NKG2D signaling did not occur in the pancreas, that NKG2D ligands were expressed in the pancreatic lymph node, that deletion of NKG2D in CD8+ T cells was required to delay diabetes, that there was reduced differentiation of CTL from islet-specific naive NKG2D KO CD8+ T cells, and that the transcriptome of NKG2D KO CTL was altered. Additionally, we found that blocking NKG2D signaling similarly reduced human CTL differentiation.
The results of our studies definitively demonstrate that NKG2D in CD8+ T cells plays a critical role in autoimmune diabetes. We show this role is to enhance CTL generation rather than the CTL effector response in islets as previously proposed. Further, our data explain the conflicting reports surrounding NKG2D’s role, as we reveal the existence of redundant, compensatory signaling that is influenced by the microbiome and sex. This inherent redundancy strongly suggests that signaling through NKG2D or its compensatory pathway is critical for islet-specific CTL generation.
Breakthrough T1D (3-SRA-2023-1412-S-B and 1-INO-2022-1118-A-N), NIH P20GM104936
Basic Autoimmunity (BA)
It is suggested that bidirectional disruptions to normal LRRK2 function break immune homeostasis and immune cell function should be carefully considered when targeting LRRK2 kinase activity in patients with PD.
Robert C. Sharp, Shannon C. Wall, Jordan C. Follet et al.· bioRxiv· 0 citations
Engineered mesenchymal stem cells overexpressing AAT and gene delivery strategies provide an effective way to achieve sustained and localized AAT expression, and are expected to overcome the current challenges in clinical translation.
The bifunctional M5542 blocked CD28 and OX40-mediated T-cell inflammation with greater immunomodulatory activity than monofunctional agents and in some assays comparable to or better than the combination of the monofunctional agents.
Michelle Downing, Allison F. Christiaansen, Ling Zhang et al.· Frontiers in Immunology· 0 citations
Findings indicate that ORMDL3 function in β-cells is dispensable in this preclinical model of T1D and underscore the need to investigate the role of ORMDL3 in immune cells, as well as the contribution of other genes within the 17q12–q21 locus to T1D susceptibility.
Qiao-Dan Ou, Evan Fletcher Jones, Kennedy Currey et al.· Biochemistry and Biophysics...· 0 citations
Abstract Regulatory CD4+ T cells (Tregs), as defined by expression of the transcription factor Foxp3, strongly depend on the cytokine interleukin 2 (IL-2) for their survival and function and are often identified by the combination of high IL-2Rα (CD25) and low IL-7Rα (CD127) expression. Nevertheless, subsets expressing...
Albert R. Jones, Peyton S Smith, H. Dooms· ImmunoHorizons· 0 citations
The management of T1D will be a blend of early diagnosis, customized immunomodulation, improved sensing of glucose, and regeneration, and in the years to come, the management of T1D will be a blend of early diagnosis, customized immunomodulation, improved sensing of glucose, and regeneration.
Jasvinder Saini, Dushyant, Jagdeep Singh et al.· Current Topics in Medicinal...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.